share_log

Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Young David

SEC ·  Feb 8 05:28
Summary by Futu AI
David Young, the President of Research & Development at Processa Pharmaceuticals, Inc. [PCSA], completed a purchase of 20,000 shares of common stock on February 6, 2024. The transaction was carried out on the open market at a price of $2.5252 per share. Following this acquisition, Young's direct holdings in the company increased to 58,387 shares. Additionally, Young has indirect holdings totaling 60,315 shares, which are held through the Young-Plaisance Revocable Trust, Family Entities, and CorLyst, LLC.
David Young, the President of Research & Development at Processa Pharmaceuticals, Inc. [PCSA], completed a purchase of 20,000 shares of common stock on February 6, 2024. The transaction was carried out on the open market at a price of $2.5252 per share. Following this acquisition, Young's direct holdings in the company increased to 58,387 shares. Additionally, Young has indirect holdings totaling 60,315 shares, which are held through the Young-Plaisance Revocable Trust, Family Entities, and CorLyst, LLC.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.